Amyris, Inc., an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products. The company delivers its No Compromise products and services in markets, such as specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
SectorBasic Materials
Phone510-450-0761
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$143.45 million
Profitability
Miscellaneous
Employees414
OptionableOptionable
Amyris (NASDAQ:AMRS) Frequently Asked Questions
What is Amyris' stock symbol?
Amyris trades on the NASDAQ under the ticker symbol "AMRS."
When did Amyris' stock split? How did Amyris' stock split work?
Shares of Amyris reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.
How were Amyris' earnings last quarter?
Amyris Inc (NASDAQ:AMRS) released its earnings results on Monday, August, 6th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.08. The biotechnology company earned $24.81 million during the quarter, compared to analyst estimates of $37.52 million. The company's revenue for the quarter was down 3.4% compared to the same quarter last year. During the same quarter last year, the company posted ($1.32) EPS. View Amyris' Earnings History.
When is Amyris' next earnings date?
What price target have analysts set for AMRS?
2 brokerages have issued 12 month price targets for Amyris' shares. Their predictions range from $8.00 to $11.00. On average, they expect Amyris' share price to reach $9.50 in the next year. This suggests a possible upside of 109.7% from the stock's current price. View Analyst Price Targets for Amyris.
What is the consensus analysts' recommendation for Amyris?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris.
What are Wall Street analysts saying about Amyris stock?
Here are some recent quotes from research analysts about Amyris stock:
- 1. According to Zacks Investment Research, "Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. " (1/15/2019)
- 2. HC Wainwright analysts commented, "We believe the company is capitalizing on its relationship with Xinfu / Yifan to monetize a portion of the long-term royalty opportunity upfront, which should lower quarterly volatility from this high-margin revenue stream while continuing to benefit from future royalty payments." (12/31/2018)
Has Amyris been receiving favorable news coverage?
News articles about AMRS stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Amyris earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are some of Amyris' key competitors?
Some companies that are related to Amyris include Codexis (CDXS), Renewable Energy Group (REGI), FutureFuel (FF), Westlake Chemical Partners (WLKP), Green Plains (GPRE), REX American Resources (REX), Green Plains Partners (GPP), Sino United Worldwide Consolidated (SUIC), Solarwindow Technologies (WNDW), CTD (CTDH), Pacific Ethanol (PEIX), Tantech (TANH), Wave Sync (WAYS), Gevo (GEVO) and Aemetis (AMTX).
Who are Amyris' key executives?
Amyris' management team includes the folowing people:
- Mr. John G. Melo, Pres, CEO & Director (Age 53)
- Ms. Kathleen Valiasek, Chief Financial Officer (Age 55)
- Mr. Eduardo Alvarez, Chief Operating Officer (Age 55)
- Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 52)
- Dr. Joel R. Cherry, Pres of R&D (Age 58)
Who are Amyris' major shareholders?
Amyris' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.47%), Northpointe Capital LLC (0.83%), WS Management Lllp (0.82%), Geode Capital Management LLC (0.53%), Northern Trust Corp (0.51%) and Pinnacle Associates Ltd. (0.45%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View Institutional Ownership Trends for Amyris.
Which major investors are selling Amyris stock?
AMRS stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, B. Riley Financial Inc. and KBC Group NV. Company insiders that have sold Amyris company stock in the last year include (Mauritius) Pte Ltd Maxwell, Frank Kung, John Melo and L John Doerr. View Insider Buying and Selling for Amyris.
Which major investors are buying Amyris stock?
AMRS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., WS Management Lllp, Pinnacle Associates Ltd., Northpointe Capital LLC, Barclays PLC, Virtus ETF Advisers LLC, Bank of America Corp DE and Principal Financial Group Inc.. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Kathleen Valiasek and Patrick Y Yang. View Insider Buying and Selling for Amyris.
How do I buy shares of Amyris?
Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amyris' stock price today?
One share of AMRS stock can currently be purchased for approximately $4.53.
How big of a company is Amyris?
Amyris has a market capitalization of $346.68 million and generates $143.45 million in revenue each year. The biotechnology company earns $-72,320,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis. Amyris employs 414 workers across the globe.
What is Amyris' official website?
How can I contact Amyris?
Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]
MarketBeat Community Rating for Amyris (NASDAQ AMRS)
MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
